BRIEF—New distribution deal for Amryt's Lojuxta

Amryt Pharma, a UK biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that it has signed an exclusive distribution agreement for Lojuxta (lomitapide) covering Romania and Bulgaria with Romastru Trading.

Romastru is a Bucharest-based pharmaceutical services company, part of Pharaon Healthcare Europe, a conglomerate which provides a wide range of services, including medical, marketing research, storage and distribution.

This is the fourth distribution agreement signed by Amryt in the last three months, and it broadens further the company’s distribution footprint for Lojuxta in Central and Eastern Europe. The company aims to complete further agreements across its in-licensed territories in Europe, Middle East and Africa as the year progresses. Amryt gained these rights from Aegerion Pharmaceuticals in December 2016.

Amryt Pharma plans to complete further agreements across its in-licensed territories in Europe, Middle East and Africa throughout 2018, the company said.

Lojuxta is a treatment for homozygous familial hypercholesterolemia (HoFH), the rare, life-threatening, genetic cholesterol disorder, and Amryt estimates that there are around 30 patients with HoFH in Romania and Bulgaria combined.